Domestic API Manufacturing and Import Substitution Consulting
The Opportunity
India's API (Active Pharmaceutical Ingredient) imports at ₹39,215 crore annually represent a significant foreign exchange drain, despite exports of ₹41,500 crore. Domestic pharmaceutical manufacturers lack specialized consulting to navigate FDI relaxation, government incentives, and compliance frameworks needed to substitute imports with indigenous production. The gap between export and import volumes signals untapped domestic manufacturing capacity.
Market Size
₹39,215 crore annual API import market in India; consulting services typically capture 1-3% of supply chain value = ₹400-1,200 crore addressable market for compliance and setup consulting
Business Model
B2B consulting firm advising domestic pharma companies on: (1) leveraging relaxed FDI norms to attract foreign capital for API facilities, (2) obtaining necessary manufacturing licenses (WHO-GMP, Schedule M compliance), (3) government subsidy applications under Production Linked Incentive (PLI) scheme, (4) import-substitution strategy and market positioning
Project-based consulting fees (₹15-50 lakh per pharma company setup engagement); Monthly retainers (₹2-5 lakh) for regulatory compliance monitoring; Success-based fees (2-5% of subsidy/incentive amount secured for clients)
Your 30-Day Action Plan
Interview 15-20 mid-sized pharma manufacturers to validate pain points around FDI relaxation, license acquisition, and import reduction strategies
Map all active government schemes (PLI Pharma, Make in India, DSIR benefits) and create a regulatory compliance checklist for API manufacturing startups
Partner with 2-3 pharma industry associations (IPMA, FAPCCI) to establish credibility and generate inbound leads from member companies
Launch landing page and LinkedIn outreach targeting 100 pharma CFOs/COOs with case study of potential ₹5-10 crore subsidy access per client
Compliance & Regulatory Angle
GST Category: Professional Services (18% GST applicable); Licenses required: Business registration, GST, professional liability insurance; Deep knowledge of Schedule M (drug manufacturing), WHO-GMP standards, DCGI approvals, State Drugs Licensing Authority processes; Familiarity with FDI approval mechanism and Cabinet press notes
Ready to Act on This Opportunity?
Generate a 7-step execution plan — validate the market, build the MVP, model the financials, map the risks, and ship in 30 days.